节点文献
OK-432联合化疗治疗癌性胸腔积液42例临床研究
Clinical research of OK-432 and chemotherapy for the patients with malignant pleural effision
【摘要】 为了评价沙培林(OK-432)联合化疗治疗癌性胸腔积液的疗效,对2000年3月~2002年7月收治的42例患者随机分为两组,治疗组胸腔内给予化疗药物和OK-432,每周1次;对照组仅用腔内化疗,药物同治疗组。结果示,治疗组CR2例,PR16例,有效率为85·7%(18/21);对照组CR1例,PR11例,有效率57·2%(12/21)。二者差异有统计学意义,Uc=2.011,P<0·05。初步研究结果提示,OK-432与化疗联用治疗癌性胸腔积液的疗效明显优于单用腔内化疗,且这种方法对患者损伤小,简便易操作,毒副反应轻微。
【Abstract】 The objective of this study was to evaluate the efficacy of OK-432 and chemotherapy for the patients with malignant pleural effusion. Forty-two patients with malignant pleural effusion were dividied into two groups: in the treatment group, 21 patients underwent introplerual therapy with Etopside and Cisplantin and intropleural injection of OK-432 5 KE every week; in the control group,21 patients only introplerual therapy with chemotherapy every week. The response rate of treatment group was 85.7%(18/21), 2 patients were CR and 16 patients PR; the response rate of the control was 57.2%(12/21),1 patient was CR and 11 patients PR.The significant difference was observed between two groups, Uc=2.011, P<0.05. In conclusion, the combined therapy with OK-432 and chemotherapy is superior to single drug of chemotherapy in patients with malignant pleural effusion. This therapy has an advantage in less injury, draining completely and smaller side effect.
【Key words】 pleurale effusion,malignant/drug therapy; picibanil/administration&dosage; treatment outcome;
- 【文献出处】 中华肿瘤防治杂志 ,Chinese Journal of Cancer Prevention and Treatment , 编辑部邮箱 ,2006年09期
- 【分类号】R730.5
- 【下载频次】35